- In February 2025, Seres Therapeutics announced the successful launch of its microbiome-based therapeutic, SER-109, in the U.S. market. This treatment targets recurrent Clostridioides difficile infection (rCDI) and is the first FDA-approved microbiome therapy. SER-109 utilizes live bacterial spores to restore gut microbiota balance, marking a significant milestone in microbiome-based healthcare
- In November 2024, Evelo Biosciences presented promising Phase 2 clinical trial data for EDP1815, a microbiome-derived therapy aimed at treating inflammatory diseases such as psoriasis and atopic dermatitis. The results demonstrated significant improvements in patient outcomes, paving the way for further development and commercialization
- In October 2024, BiomeSense unveiled its advanced microbiome monitoring platform at the Microbiome Movement Conference. This platform provides real-time microbiome analysis, enabling personalized healthcare solutions and accelerating research in microbiome-targeted therapies
- In September 2024, Nestlé Health Science expanded its portfolio of microbiome-based nutritional products with the launch of Boost Gut+, a probiotic-enriched supplement designed to improve digestive health and immunity. The product leverages cutting-edge microbiome research to cater to the growing demand for functional foods
